Falsolieva 250 mg contains Fulvestrant, a hormonal anticancer medicine classified as a Selective Estrogen Receptor Degrader (SERD). It works by binding to estrogen receptors and causing their degradation, thereby blocking estrogen-driven growth of hormone-dependent breast cancer cells.

Fulvestrant Injection is indicated for treatment of:

1. Hormone receptor–positive (ER+) breast cancer

2. Locally advanced or metastatic breast cancer in postmenopausal women

3. Breast cancer after progression on anti-estrogen therapy (e.g., tamoxifen, aromatase inhibitors)

Common side effects:

• Injection-site pain

• Hot flashes

• Nausea

• Fatigue

• Headache

• Joint or muscle pain

Serious side effects:

• Liver function abnormalities

• Thromboembolic events (rare)

• Hypersensitivity reactions

 Use with caution in patients with liver impairment.

Standard recommended dose:

• 500 mg intramuscularly

Dosing schedule:

• Day 1: 500 mg

• Day 15: 500 mg

• Day 29 and monthly thereafter: 500 mg

 Given as two separate IM injections (250 mg each), one in each gluteal muscle.